7SS.F Brii Biosciences Limited

Healthcare Biotechnology Frankfurt Exchange
0.1090 EUR
Close of Nov 11, 2026
0.0855 0.2020
Market cap
EUR 78.6M
P/E
-
P/B
0.26x
ROE
-9.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 7SS.F undervalued?

Graham number

The Graham number of Brii Biosciences Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Brii Biosciences Limited fundamental analysis

No fundamental analysis for Brii Biosciences Limited yet.

Brii Biosciences Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Brii Biosciences Limited

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for f…

Full company profile